SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001558370-22-001035
Filing Date
2022-02-11
Accepted
2022-02-11 09:01:28
Documents
13
Period of Report
2022-02-11
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K nrxp-20220211x8k.htm   iXBRL 8-K 41875
  Complete submission text file 0001558370-22-001035.txt   207294

Data Files

Seq Description Document Type Size
2 EX-101.SCH nrxp-20220211.xsd EX-101.SCH 4470
3 EX-101.DEF nrxp-20220211_def.xml EX-101.DEF 14720
4 EX-101.LAB nrxp-20220211_lab.xml EX-101.LAB 21451
5 EX-101.PRE nrxp-20220211_pre.xml EX-101.PRE 16038
7 EXTRACTED XBRL INSTANCE DOCUMENT nrxp-20220211x8k_htm.xml XML 7447
Mailing Address 1201 N. MARKET STREET SUITE 111 WILMINGTON DE 19801
Business Address 1201 N. MARKET STREET SUITE 111 WILMINGTON DE 19801 484-254-6134
NRX Pharmaceuticals, Inc. (Filer) CIK: 0001719406 (see all company filings)

IRS No.: 822844431 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38302 | Film No.: 22617005
SIC: 2834 Pharmaceutical Preparations